Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer

Silexion Therapeutics Corp

SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.
Approval follows positive preclinical anti-tumor data and completed toxicology studies.
Human trials expected to begin in Q2 2026; also planning German application in current quarter.
Company plans to pursue additional KRAS-driven indications including colorectal and lung cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.